RadNet, Inc.

RDNT Nasdaq CIK: 0000790526

Company Information

Industry Services-Medical Laboratories
SIC Code 8071
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 1510 COTNER AVE, LOS ANGELES, CA, 90025
Mailing Address 1510 COTNER AVE, LOS ANGELES, CA, 90025
Phone 3104787808
Fiscal Year End 1231
EIN 133326724

Financial Overview

FY2025

$1.09B
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
4 Insider stock transaction report March 23, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC

Annual Reports

10-K March 2, 2026
  • Strong FY2023 financial performance with 10% revenue growth to $1.65 billion and 12% Adjusted EBITDA growth to $350 million.
  • Aggressive expansion strategy through 25 acquisitions in 2023, growing network to over 370 centers, with plans for 15-20 more in 2024.
View Analysis

Material Events

8-K Acquisition January 30, 2026
Medium Impact
  • RadNet acquired Cimar (UK) Limited, strengthening its AI and teleradiology capabilities.
  • The acquisition expands RadNet's international presence and technological offerings, particularly in cloud-native platforms for diagnostics.
View Analysis

Insider Trading

STRONG SELL 2 insiders 8 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 8071)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.